CXCL8/IL-8 Antibody [Alexa Fluor® 488]

• Reactivity: Hu
• Applications: WB, IHC, B/N, ICC/IF
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 488

CXCL8/IL-8 Antibody [Alexa Fluor® 488] Summary

• Immunogen: E. coli-derived recombinant human IL-8/CXCL8
  Ser28-Ser99
  Accession # P10145
• Specificity: Detects human IL-8/CXCL8 in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry
  • Immunohistochemistry
  • Neutralization
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL8/IL-8 Antibody [Alexa Fluor® 488]

• 3-10C
• AMCF-I
• C-X-C motif chemokine 8
• CXCL8
• CXCL8SCYB8
• Emoctakin
• GCP1
• GCP-1TSG-1
• IL8
• IL-8
• interleukin 8
• K60
• LAI
• LECT
• LUCT
• LYNAP
• MDNCF
• MDNCFb-ENAP
• member 8
• MONAP
• MONAPGCP1
• NAF
• NAP1
• NAP-1NAP1
• NCF
• Neutrophil-activating protein 1
• Protein 3-10C
• T cell chemotactic factor
• T-cell chemotactic factor
• TCF
• TSG1

Background

CXCL8 was originally discovered and purified independently by a number of laboratories as a neutrophil chemotactic and activating factor. It was also referred to as neutrophil chemotactic factor (NCF), neutrophil activating protein (NAP), monocyte-derived neutrophil chemotactic factor (MDNCF), T-lymphocyte chemotactic factor (TCF), granulocyte chemotactic protein (GCP) and leukocyte adhesion inhibitor (LAI). Many cell types, including monocyte/macrophages, T cells, neutrophils, fibroblasts, endothelial cells, keratinocytes, hepatocytes, chondrocytes, and various tumor cell lines, can produce CXCL8 in response to a wide variety of pro-inflammatory stimuli such as exposure to IL-1, TNF, LPS, and viruses. CXCL8 is a member of the alpha (CXC) subfamily of chemokines, which also includes platelet factor 4, GRO, IP-10, etc.

CXCL8 is a potent chemoattractant for neutrophils. In addition, CXCL8 also has a wide range of other pro-inflammatory effects. CXCL8 causes degranulation of neutrophil specific granules and azurophilic granules. CXCL8 induces expression of the cell adhesion molecules CD11/CD18 and enhances the adherence of neutrophils to endothelial cells and sub-endothelial matrix proteins. Besides neutrophils, CXCL8 is also chemotactic for basophils, T cells and eosinophils. CXCL8 has been reported to be a co-mitogen for keratinocytes and was also shown to be an autocrine growth factor for melanoma cells. CXCL8 was also reported to be angiogenic both in vivo and in vitro.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P10145()